("EKF" or the "Company", or the "Group")
Notice of interim results
Investor presentation
Investor Presentation
https://www.investormeetcompany.com/ekf-diagnostics-holdings-plc/register-investor
Investors who already follow EKF on the
A recording of the presentation, a PDF of the slides used, and responses to the Q&A session will be available on the
|
|
|||
|
Julian Baines, Executive Chair |
via Walbrook PR |
||
|
Gavin Jones, Chief Executive Officer |
|
||
|
Stephen Young, Chief Financial Officer
|
|
||
|
|
Tel: +44 (0)20 7496 3000 |
||
|
Phil Davies / Oliver Platts |
|
||
|
|
|
||
|
|
Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com |
||
|
Paul McManus / Alice Woodings |
Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654 |
||
About
EKF is an AIM-listed global diagnostics business focussed on:
|
● |
Point-of-Care analysers in the key areas of Hematology and Diabetes |
|
● |
Life Sciences offers contract fermentation services for clinically important enzymes and proteins, and the manufacture of Beta-Hydroxybutyrate (β-HB), used as a quantitative ketone test to identify patients suffering from diabetic ketoacidosis, as well as in many other clinical applications. |
EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the